Vertiflex’s Superion Interspinous Spacer Gets FDA Panel Date
This article was originally published in The Gray Sheet
Executive Summary
FDA’s Orthopaedic and Rehabilitation Devices Panel will meet in December to consider Vertiflex’s submission to support approval of the Superion interspinous spacer to treat moderate lumbar spinal stenosis.
You may also be interested in...
Motion Is Back In Spine Market
In less than a month, the US Food and Drug Administration (FDA) recently approved three spine PMAs, two for cervical disc replacement devices, and there are two more cervical discs in the queue for near-term PMA approval. All of this activity suggests the $122 million US cervical disc market is about to gear up.
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.